Onco-Innovations Reveals Promising Results for Cancer Treatment Technology

Onco-Innovations Limited has announced advancements in its licensed Polynucleotide Kinase 3'-Phosphatase (PNKP) inhibitor technology. This innovation demonstrated increased sensitivity of cancer cells to radiation in an animal study from researchers at the University of Alberta. The technology targets PTEN-deficient cells, reducing their DNA repair capabilities, and improving the efficacy of radiation therapy in colorectal cancer models.

The study highlights the potential for these inhibitors to allow for lower radiation doses, possibly minimizing side effects. Focusing on cancer vulnerabilities while sparing healthy cells, the technology aims to offer more precise treatment. CEO Thomas O'Shaughnessy expressed optimism about the future impact of this technology on patient outcomes.

In addition, Onco-Innovations has hired Venture Liquidity Providers Inc. to provide market-making services for its shares, ensuring better market conditions on the Canadian Securities Exchange.